跳至主要内容
临床试验/EUCTR2008-004831-39-SE
EUCTR2008-004831-39-SE进行中(未招募)不适用

A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of MK-0736 When Added to Ongoing Therapy With Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) in Patients With Diabetes and Hypertension - MK-0736 Dose Ranging Study

MSD0 个研究点目标入组 567 人开始时间: 2008年10月14日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
MSD
入组人数
567

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • •1) Patient is = 18 years of age and = 75 years of age
  • •2) Patient has Type II diabetes (T2DM) and:
  • •HbA1c = 7.0% and <= 10.0 %.
  • •Is not newly diagnosed (within 3 months of Visit 1)
  • •Is not taking new or recently adjusted anti-diabetic pharmacotherapy (with the exception of ±10 units of insulin) within 3 months of Visit 1.
  • •3) A patient who is of reproductive potential agrees to remain abstinent* or use (or have their partner use) 2 acceptable methods of birth control for the duration of the study. Acceptable methods of birth control are: intrauterine device (IUD), diaphragm with spermicide, condom, vasectomy, and hormonal contraception.
  • •4) At Randomization, SiSBP = 120 mmHg and < 160 mmHg and SiDBP = 85 mmHg and < 100 mmHg
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range

排除标准

  • •1) Patient has a history of type 1 diabetes mellitus or history of ketoacidosis.
  • •2) Patient has decompensated valvular disease, presence of hemodynamically significant obstructive valvular disease or cardiomyopathy.
  • •3) Patient has a history of malignancy = 5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
  • •4) Patient is human immunodeficiency virus (HIV) positive (as assessed by medical history).
  • •5) Patient has received treatment with any investigational drugs within the past 30 days.
  • •6) Patient does not agree to comply with restrictions on alcohol (average allowed intake of < 14 drinks per week and no alcohol intake within 24 hours prior to all clinic visits requiring fasting laboratory analysis) or patient has a history of alcohol or drug abuse within the past 3 years.
  • •7) Patient has BMI = 41 kg/m2

研究者

发起方
MSD

相似试验

进行中(未招募)
1 期
.a.Homozygous Familial Hypercholesterolemia (HoFH)MedDRA version: 14.1Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 100000004861
EUCTR2012-002434-37-ITMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc45
进行中(未招募)
不适用
A Worldwide, Multicenter, Double-Blind, Randomized, Parallel Study to Evaluate the Efficacy of MK-0524 to Improve Tolerability of Extended Release Niacin - Effect of an Investigational Compound on Tolerability of Extended Release NiaciMedDRA version: 8.1Level: LLTClassification code 10020604Term: HypercholesterolemiaHypercholesterolemia
EUCTR2006-003107-39-DEMerck & Co825
进行中(未招募)
1 期
A worldwide placebo-controlled study to evaluate the additional lipid benefits of extended release (ER) niacin/laropiprant when taken with current lipid-modifying therapy in individuals with abnormal lipidsPrimary Hypercholesterolemia or Mixed DyslipidemiaMedDRA version: 14.1 Level: LLT Classification code 10020604 Term: Hypercholesterolemia System Organ Class: 100000004861MedDRA version: 14.1 Level: LLT Classification code 10058110 Term: Dyslipidemia System Organ Class: 100000004861
EUCTR2010-021627-27-GBMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.1,224
进行中(未招募)
不适用
A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the Long-term Efficacy, Safety and Tolerability of Extended-Release (ER) Niacin and Laropiprant (ERN/LRPT) in Patients with DyslipidemiaDyslipidemia
EUCTR2009-012772-27-ATMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.1,125
进行中(未招募)
不适用
A worldwide placebo-controlled study to evaluate the additional lipid benefits of extended release (ER) niacin/laropiprant when taken with current lipid-modifying therapy in individuals with abnormal lipidsPrimary Hypercholesterolemia or Mixed DyslipidemiaMedDRA version: 14.1Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 14.1Level: LLTClassification code 10058110Term: DyslipidemiaSystem Organ Class: 10027433 - Metabolism and nutrition disorders
EUCTR2010-021627-27-BGMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.1,224